Trial Profile
A Phase 3 Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Apr 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Vincristine
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms RELEVANCE
- Sponsors Celgene Corporation
- 10 Apr 2024 Planned End Date changed from 1 Jun 2024 to 30 Apr 2024.
- 10 Apr 2024 Planned primary completion date changed from 1 Jun 2024 to 30 Apr 2024.
- 13 Dec 2022 Results assessing the prognostic value of baseline TMTV for FL patients with previously untreated advanced FL included in in the phase 3 RELEVANCE trial comparing R2 vs R-chemo with both regimens followed by rituximab maintenance therapy (NCT01476787 and NCT01650701), presented at the 64th American Society of Hematology Annual Meeting and Exposition.